(19)
(11) EP 3 438 986 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.08.2024 Bulletin 2024/34

(45) Mention of the grant of the patent:
10.07.2024 Bulletin 2024/28

(21) Application number: 17306035.1

(22) Date of filing: 02.08.2017
(51) International Patent Classification (IPC): 
G16H 20/17(2018.01)
G16H 50/50(2018.01)
A61M 5/142(2006.01)
G16H 40/40(2018.01)
A61B 5/145(2006.01)
A61M 5/172(2006.01)
(52) Cooperative Patent Classification (CPC):
A61B 5/14532; A61M 2005/14208; A61M 2005/1726; A61M 2230/201; G16H 40/40; G16H 50/50; G16H 20/17

(54)

CLOSED-LOOP BLOOD GLUCOSE CONTROL SYSTEMS AND METHODS

BLUTGLUCOSEKONTROLLSYSTEME UND -VERFAHREN MIT GESCHLOSSENER SCHLEIFE

SYSTÈMES ET PROCÉDÉS DE CONTRÔLE DE GLYCÉMIE À BOUCLE FERMÉE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(43) Date of publication of application:
06.02.2019 Bulletin 2019/06

(73) Proprietor: Diabeloop
38000 Grenoble (FR)

(72) Inventors:
  • Desir, Chesner
    155-157 Cours Berriat 38000 Grenoble (FR)
  • Lachal, Sylvain
    155-157 Cours Berriat 38000 Grenoble (FR)
  • Franco, Celine
    155-157 Cours Berriat 38000 Grenoble (FR)

(74) Representative: Pellegri, Michel Pascal Romain 
Cabinet Vulpelex 52 Rue Montgolfier
69006 Lyon
69006 Lyon (FR)


(56) References cited: : 
WO-A2-2007/116226
US-A1- 2016 354 543
   
  • "DTU Compute-Technical Report", vol. 13, 2013, TECHNICAL UNIVERSY OF DENMARK, ISSN: 1601-2321, article ANNE KATRINE DUUN-HENRIKSEN ET AL: "Modelling the Effect of Exercise on Insulin Pharmacokinetics in "Continuous Subcutaneous Insulin Infusion" Treated Type 1 Diabetes Patients", XP055438255
  • DIMITRI BOIROUX ET AL: "Model Predictive Control Algorithms for Pen and Pump Insulin Administration", 20 October 2015 (2015-10-20), pages 15 - 24, XP002776941, Retrieved from the Internet <URL:http://orbit.dtu.dk/files/57023470/phd283_Boiroux_D.pdf> [retrieved on 20171113]
  • SOEBORG T ET AL: "Absorption kinetics of insulin after subcutaneous administration", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER AMSTERDAM, NL, vol. 36, no. 1, 31 January 2009 (2009-01-31), pages 78 - 90, XP025860044, ISSN: 0928-0987, [retrieved on 20081105], DOI: 10.1016/J.EJPS.2008.10.018
  • ROMAN HOVORKA ET AL: "Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes; Controlling glucose", PHYSIOLOGICAL MEASUREMENT, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 25, no. 4, 1 August 2004 (2004-08-01), pages 905 - 920, XP020074167, ISSN: 0967-3334, DOI: 10.1088/0967-3334/25/4/010
  • JALLON P ET AL: "Personalization of a compartmental physiological model for an artificial pancreas through integration of patient's state estimation", 2017 39TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), IEEE, 11 July 2017 (2017-07-11), pages 1453 - 1456, XP033152274, DOI: 10.1109/EMBC.2017.8037108
  • DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2018, GRADEL A K J ET AL: "Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability.", Database accession no. NLM30116732
  • GRADEL A K J ET AL: "Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability.", JOURNAL OF DIABETES RESEARCH 2018, vol. 2018, 2018, pages 1205121, ISSN: 2314-6753
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).